In an R&D and clinical trial setting, we assisted in the identification and prioritization of cancer neoantigen for targeted immunotherapy.
We developed an AI-driven solution that seamlessly integrates DNA and RNA sequencing via a robust NGS variant calling pipeline. Using machine learning to prioritize neoantigens for cancer therapies, we created a scalable and interactive hybrid cloud data analysis and visualization solution.